US · Healthcare · Biotechnology
EPS came in at 3.29 against a street estimate of 0.78 — a beat of 321.8%.
Analysts rate Ascendis Pharma AS a strong buy (20 buy, 0 hold, 0 sell out of 20) with an average price target of $305.03.
| Fund | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 0.34% |
| Neuberger Berman Group LLC | 0.22% |
| ODDO BHF Asset Management SAS | 0.20% |
| Quadrature Capital Limited | 0.06% |
| Skopos Labs Inc | 0.01% |
| Ferguson Wellman Capital Management, Inc | 0.00% |
| Dearborn Partners LLC | 0.00% |
| CWM, LLC duplicate | 0.00% |
| Document | Date |
|---|---|
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • On October 16, 2026, Ascendis Pharma announced a positive opinion from the European Medicines Agency’s Committee for Medicinal Pro | 2026-10-16 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Share capital is DKK 66,400,738, divided into shares of DKK 1 each, and is fully paid up. • As of 13 October 2026, the company ha | 2026-10-14 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • The document is Ascendis Pharma A/S’s Articles of Association, dated 29 September 2026; it is not an operating or financial-result | 2026-09-29 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • On September 14, 2026, Ascendis Pharma announced it will regain exclusive rights to develop, manufacture, and commercialize TransC | 2026-09-15 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Ascendis Pharma’s Board authorized a share repurchase program of up to $400 million. • The authorization was announced on Septemb | 2026-09-15 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Ascendis Pharma reported Week 52 results from the open-label sentinel cohort of its reACHin Phase 2 trial evaluating once-weekly T | 2026-09-09 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • The document is Ascendis Pharma A/S’s Articles of Association dated 8 September 2026. • Registered share capital is DKK 66,380,46 | 2026-09-09 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • Fiscal year ended December 31, 2025; financial statements use IFRS and are presented in euros. • Net loss was €228 million in 202 | 2026-02-11 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ascendis Pharma AS — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.